OBJECTIVE: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. STUDY DESIGN: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. RESULTS: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤ .001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of ≥ 250 mL after treatment. CONCLUSION: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.
RCT Entities:
OBJECTIVE: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. STUDY DESIGN: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. RESULTS: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤ .001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of ≥ 250 mL after treatment. CONCLUSION: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.
Authors: Neil S Wenger; Carol P Roth; William J Hall; David A Ganz; Vincenza Snow; James Byrkit; Edward Dzielak; David J Gullen; Thomas R Loepfe; Carl Sahler; Qianna Snooks; Robin Beckman; John Adams; Mayde Rosen; David B Reuben Journal: Arch Intern Med Date: 2010-10-25
Authors: Jeanette S Brown; Kristin S McNaughton; Jean F Wyman; Kathryn L Burgio; Richard Harkaway; Donald Bergner; David S Altman; Joel Kaufman; Keith Kaufman; Cynthia J Girman Journal: Urology Date: 2003-04 Impact factor: 2.649
Authors: Jeanette S Brown; Catherine S Bradley; Leslee L Subak; Holly E Richter; Stephen R Kraus; Linda Brubaker; Feng Lin; Eric Vittinghoff; Deborah Grady Journal: Ann Intern Med Date: 2006-05-16 Impact factor: 25.391
Authors: Louis S Matza; Christine L Thompson; Joel Krasnow; Jessica Brewster-Jordan; Teresa Zyczynski; Karin S Coyne Journal: Neurourol Urodyn Date: 2005 Impact factor: 2.696
Authors: Ethan M Balk; Gaelen P Adam; Katherine Corsi; Amanda Mogul; Thomas A Trikalinos; Peter C Jeppson Journal: J Gen Intern Med Date: 2019-05-06 Impact factor: 5.128
Authors: William D Winkelman; Ann Warsi; Alison J Huang; Michael Schembri; Rebecca G Rogers; Holly E Richter; Deborah L Myers; Stephen R Kraus; Karen C Johnson; Rachel Hess; Thomas Gregory; Catherine S Bradley; Lily A Arya; Jeanette S Brown; Katie L Stone; Leslee L Subak Journal: Female Pelvic Med Reconstr Surg Date: 2018 Mar/Apr Impact factor: 2.091
Authors: Rachel Hess; Alison J Huang; Holly E Richter; Chiara C Ghetti; Vivian W Sung; Elizabeth Barrett-Connor; W Thomas Gregory; JoAnn V Pinkerton; Catherine S Bradley; Stephen R Kraus; Rebecca G Rogers; Leslee L Subak; Karen C Johnson; Lily A Arya; Michael Schembri; Jeanette S Brown Journal: Am J Obstet Gynecol Date: 2013-05-06 Impact factor: 8.661
Authors: William D Winkelman; Alison J Huang; Michael Schembri; Rebecca G Rogers; Holly Richter; Deborah L Myers; Stephen R Kraus; Karen C Johnson; Rachel Hess; Tomas Gregory; Catherine S Bradley; Lily Arya; Janette S Brown; Leslee L Subak Journal: Female Pelvic Med Reconstr Surg Date: 2017 Mar/Apr Impact factor: 2.091